Following a full submission.
Tigecycline (Tygacil) is accepted for restricted use within NHS Scotland for the treatment of complicated skin and soft-tissue infections.
Tigecycline is associated with clinical cure rates in patients with complicated skin and skin structure infections non-inferior to those with a combination of a glycopeptide and a monocyclic beta-lactam antibiotic.
It is restricted to use as a 2nd or 3rd line agent under the advice of local microbiologists or specialists in infectious diseases.
Download detailed advice46KB (PDF)
- Medicine name:
- tigecycline 50mg vial of powder tigecycline for intravenous infusion (Tygacil)
- SMC ID:
- Complicated skin and soft-tissue infections
- Pharmaceutical company
- Wyeth Pharmaceuticals
- BNF chapter
- Submission type
- Date advice published
- 10 July 2006